echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Pharmaceutical pattern changes again, Roche reaches the summit in 2022, with Novartis and Pfizer in the second and third places

    Pharmaceutical pattern changes again, Roche reaches the summit in 2022, with Novartis and Pfizer in the second and third places

    • Last Update: 2016-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: pharmaceutical economic news 2016-09-19, evaluatepharma released the latest report "2016 global pharmaceutical outlook", which predicted the development trend of the global pharmaceutical industry from the current to 2022 According to the report, during this period, the global prescription drug market will expand at an annual growth rate of 6.3% and reach a milestone of over US $1 trillion by 2022 At the same time, Novartis and Roche will compete in the global pharmaceutical No.1 race, which will smile to the end by a narrow margin According to the forecast, Roche's prescription drug sales will reach 52.6 billion US dollars in 2022 (38.7 billion US dollars in 2015), with an annual growth rate of 4%; Novartis is only behind with a gap of 100 million US dollars, with prescription drug sales of 52.5 billion US dollars in 2022 (42.5 billion US dollars in 2015); Pfizer, Sanofi and Johnson & Johnson are next in order( Johnson & Johnson, Merck, GlaxoSmithKline, etc The report also points out that Roche is facing a more serious threat of bio similar drugs than Novartis, and its best-selling drugs rituxan and Avastin are expected to be challenged by bio similar drugs from 2020 The driving force for the continuous expansion of prescription drug market comes from some "rising stars" Roche's tumor immunotherapy drug tecentriq is one of them By 2022, the drug will be among the best-selling drugs in the world In addition, some new drugs from Gilead, Biogen and GSK have great potential, according to the report It is worth noting that celgene and shire are expected to maintain double-digit annual growth rates of 16% and 19% respectively during this period In 2015, Pfizer boasted $43.1 billion in sales, and the report predicted that its sales would reach $49.1 billion in 2022 In last year's report, Novartis was seen as the global pharmaceutical overlord in 2020 Evaluatepharma listed Roche's R & D line as the most valuable R & D asset in the pharmaceutical industry, although the company's strategy also carries some risks Its candidate drugs in the fields of multiple sclerosis, Alzheimer's disease, hemophilia and macular degeneration make its overall R & D line worth as much as 43.2 billion US dollars, far ahead of Novartis's 24.1 billion US dollars and AstraZeneca's 23.2 billion US dollars In the value ranking of R & D line, it is followed by Eli Lilly, abbvie, Pfizer, Sanofi, Xinji medicine, Baijian and Johnson & Johnson In the next few years, the pharmaceutical industry will continue to grow steadily, but the report also points out that there are still some unstable factors, such as pricing pressure, challenges of bio similar drugs and failure of clinical trials As the medical system struggles with rising costs, the pressure of medical cost control will also become a roadblock for the growth of the drug market.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.